Cipla Quarterly Results for Trading Insights
In Mar 2026, Cipla (CIPLA) reported revenue ₹6,612 Cr and net profit ₹543 Cr — revenue -4.0% YoY. For annual financials, live price and key ratios, visit CIPLA share price screener.
CIPLA Quarterly Results — Revenue, Profit & EPS Highlights
Cipla latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore CIPLA price movement history to track price trends across different timeframes.
- Revenue of ₹6,612 Cr in Mar 2026 (-14.3% vs Sept 2025, -4.0% vs Mar 2025)
- Net Profit of ₹543 Cr in Mar 2026 (-59.9% vs Sept 2025, -55.3% vs Mar 2025)
- EBITDA of ₹1,026 Cr in Mar 2026 (-49.3% vs Sept 2025)
- Operating Margin of 14.0% in Mar 2026 (-10.0pp vs Sept 2025)
- Earnings Per Share of ₹6.87 in Mar 2026 (-58.9% vs Sept 2025)
Cipla Quarterly Results — Revenue, EBITDA, Net Profit & EPS
CIPLA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 6,612 | 7,716 | 6,887 | 7,096 | 7,169 | -14.3% | -4.0% |
| Net Profit (₹ Cr) | 543 | 1,353 | 1,214 | 1,292 | 674 | - | - |
| EBITDA (₹ Cr) | 1,026 | 2,022 | 1,695 | 1,916 | 1,074 | - | - |
| EPS (₹) | 6.87 | 16.73 | 15.13 | 16.07 | 8.37 | - | - |
| Operating Margin (%) | 14.0% | 24.0% | 21.0% | 24.0% | 12.0% | - | - |
CIPLA Share Price Trend — 1-Year Movement Across Quarterly Results
Cipla 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Browse CIPLA balance sheet details for revenue, profit, balance sheet and cash flow data.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
CIPLA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Cipla latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹469,405.89 Cr | 1941.1 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 171.8 |
|
Divis Laboratories
Mar 2026 |
₹194,269.91 Cr | 7248.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 256.0 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹191,454.40 Cr | 4961.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.1 |
|
Zydus Life Science
Mar 2026 |
₹115,616.29 Cr | 1108.7 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 87.6 |
|
Lupin
Mar 2026 |
₹110,051.30 Cr | 2370.5 | 7,533 | 1,469 | +8.8% | +34.1% | 19.5% | 68.1 |
All amounts in ₹ Crores